Cronin has worked at Moderna since 2021, when she was brought on to market the biotech company’s COVID-19 vaccine.

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $25.0 to $70.0 for Moderna over the recent three months. In terms of liquidity ...

We recently published a list of 10 Stocks To Trade Without Tariffs And Interest Rate Fears. In this article, we are going to ...

Federal leaders looked to Ralph Baric to end the pandemic. Their critics blamed it on him. Now, the White House wants to slash his funding.

What’s Up With mRNA Research? A research nurse holds an injection of a BioNTech mRNA cancer immunotherapy for non-small cell ...

U.S. health agency leadership and policymakers seem intent on undermining trust in mRNA, the technology that saved millions ...

Just a few years since pioneering a Covid-19 vaccine, Moderna faces a hostile political environment and a looming patent ...

USPTO Finds Claims Of Two Of Moderna’s mRNA Patents Unpatentable: What’s Next In The Vaccine Wars? Legal News and Analysis - ...

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing ...

The updated mRNA-1273.815 COVID-19 vaccine was significantly protective against hospitalization and medically attended outcomes among adults in the United States.

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...